Fech, Viktor; Alberts, Ian; Rominger, Axel; Afshar-Oromieh, Ali (2019). PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography (In Press). Nuklearmedizin Thieme 10.1055/a-0895-5078
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Fech_Case Report.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (994kB) |
A patient with bone metastases of prostate cancer was referred for 68Ga-PSMA-11 PET/CT. Compared to a 68Ga-PSMA-11 PET/CT four months previously, the CT-component of the current PET/CT showed morphological progress in all lesions despite continuous therapy with docetaxel and denosumab. Contrarily, the PET-component showed a reduction of tracer-uptake, which correlated with PSA decrease between the two PET/CT-scans (16.2 ng/ml vs. 3.1 ng/ml). This case highlights 68Ga-PSMA-11 PET/CT as a promising tool for therapy monitoring of prostate cancer and could serve as a basis for a novel monitoring strategy. Volume progress shown by CT must not be classified as tumor progress, but as bone remodeling following effective therapy.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine |
UniBE Contributor: |
Fech, Viktor, Alberts, Ian Leigh, Rominger, Axel Oliver, Afshar Oromieh, Ali |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0029-5566 |
Publisher: |
Thieme |
Language: |
Multilingual |
Submitter: |
Sabine Lanz |
Date Deposited: |
18 Dec 2019 10:14 |
Last Modified: |
05 Dec 2022 15:30 |
Publisher DOI: |
10.1055/a-0895-5078 |
PubMed ID: |
31083752 |
BORIS DOI: |
10.7892/boris.132408 |
URI: |
https://boris.unibe.ch/id/eprint/132408 |
Actions (login required)
 |
Edit item |